Article Text

CARPHOLOGY by Rajendra

Statistics from

Immunisation in Alzheimer’s disease

Although immunisation with Abeta(42) resulted in clearance of amyloid plaques in patients with Alzheimer’s disease, this did not prevent progressive neurodegeneration. This was what researchers found in a randomised, placebo-controlled phase I trial which looked at the long-term effects of Abeta42 immunisation in Alzheimer’s disease. The follow-up study of this trial which they began in 2000 was completed in September, 2006. Plaques were assessed in terms of the percentage area of the cortex with Abeta immunostaining and by the histological features reflecting removal of plaque.

Lancet 2008;372:216–23.

Dimebon in Alzheimer’s disease

Dimebon, an antihistaminic, was safe, well tolerated, and significantly improved the clinical course of patients with mild-to-moderate Alzheimer’s disease, say researchers from Russia. They conducted a multicentre, randomised, double-blind, placebo-controlled study on 183 patients, which looked …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.